REPLReplimune Group, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$317M
- 23% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$263M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$118M | −$177M | −$235M | −$262M | −$320M | 22% |
| Net income | −$118M | −$174M | −$216M | −$247M | −$314M | 27% |
| Operating cash flow | −$82M | −$128M | −$185M | −$192M | −$280M | 46% |
| Capex | $2M | $2M | $6M | $7M | $4M | 37% |
| Stock-based comp | $24M | $28M | $34M | $35M | $32M | 7.9% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2026 | $6M | $4M | 43 | — |
| FY2025 | $4M | $5M | 55 | — |
| FY2024 | $6M | $1M | 46 | — |